Company intelligence / Profile preview

Remedy Pharmaceuticals

New York City, New York, United Statesremedypharmaceuticals.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

Remedy's lead drug CIRARA (active ingredient: glyburide) has shown promising results in treating Large Hemispheric Infarction (LHI), particularly in patients with lesion volumes between 50ml and 125ml who undergo endovascular therapy (EVT). The drug demonstrated an odds ratio of 8.19 favoring treatment over placebo in this patient population. The company is planning a pivotal Phase 3 trial to confirm CIRARA's effect in LHI patients with lesion volumes below 125 mL who undergo EVT.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

CIRARA

Phase 3

Indications: Large hemispheric infarction, Ischemic stroke

Partnerships

Previously partnered with Biogen (CIRARA was returned to Remedy)

Beyond the preview

Go deeper on Remedy Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Remedy Pharmaceuticals.

Explore the full profile